SynDevRx, Inc. Information

Cancer meets obesity - Metabolic dysfunction (obesity. diabetes, etc.) makes cancer more aggressive. SynDevRx is pioneering the metabo-oncology field with a first-in-class therapeutic targeting cancer patients with metabolic dysfunction. This overlooked patient population is estimated at >700,000/year in the US. We are in multiple Phase 2 clinical studies in breast cancer and prostate cancer with a unique value proposition. Our lead asset 'evexomostat' has dual action - anti-angiogenic/anti-tumor plus a potent and clinically validated metabolic correction activity.